High-Dose Fluzone is More Efficacious for Adults ≥65 Years
For patients 65 years and older, high-dose Fluzone (HD-IIV) is more effective than standard-dose influenza vaccines, including standard-dose Flucelvax (Mfluvisa), and should be the preferred choice. The evidence consistently demonstrates superior protection across multiple clinically important outcomes.
Evidence Supporting High-Dose Fluzone
The most recent and comprehensive meta-analysis of 8 randomized clinical trials including over 605,000 participants aged ≥65 years demonstrates that HD-IIV significantly outperforms standard-dose vaccines 1:
- 38.5% greater protection against influenza hospitalizations (95% CI: 26.5%-48.5%)
- 31.2% greater protection against laboratory-confirmed influenza (95% CI: 19.3%-41.4%)
- 11.5% greater protection against pneumonia/influenza hospitalizations (95% CI: 5.9%-16.8%)
- 7.5% greater protection against cardiorespiratory hospitalizations (95% CI: 4.7%-10.3%)
- 3.3% greater protection against all-cause hospitalizations (95% CI: 1.8%-4.8%)
These findings are corroborated by real-world data from the 2024/25 Danish influenza season, where high-dose QIV demonstrated vaccine effectiveness of 48% compared to 33% for standard-dose QIV 2.
Guideline Recommendations
Current CDC/ACIP guidelines explicitly state that high-dose inactivated influenza vaccine (HD-IIV3) is approved specifically for persons aged ≥65 years, while it is not approved for younger populations 3. Portuguese multisociety guidelines strongly endorse high-dose vaccines for older adults, noting that "high-dose influenza vaccines have consistently outperformed standard-dose vaccines across various trials and methodologies" 4.
Age-Stratified Considerations
The relative vaccine effectiveness increases with age 5:
- Most consistent benefit in adults ≥75 years, where HD vaccine shows statistically significant superiority
- Adults 65-74 years show more modest but still meaningful improvements
- Adults ≥85 years demonstrate the most robust benefit across all influenza seasons
Comparison with Mfluvisa (Flucelvax)
Mfluvisa is a standard-dose cell-culture-based quadrivalent vaccine approved for ages ≥6 months 6. While it represents a valid standard-dose option, there are no head-to-head trials directly comparing it to high-dose Fluzone. However, the extensive evidence base comparing high-dose to standard-dose vaccines (regardless of manufacturing platform) consistently favors high-dose formulations in the ≥65 population 7, 8, 1.
Clinical Impact on Morbidity and Mortality
The high-dose vaccine meaningfully reduces morbidity through decreased hospitalizations, which directly impacts quality of life by preventing:
- ICU admissions
- Invasive mechanical ventilation
- Bacterial pneumonia complications
- Functional decline in nursing home residents 4
While all-cause mortality differences were not statistically significant in the meta-analysis (rVE 0.9%; 95% CI: -2.1% to 3.8%) 1, the substantial reductions in hospitalizations represent clinically meaningful improvements in morbidity and quality of life.
Important Caveats
- High-dose vaccines are associated with slightly higher rates of mild injection site reactions, though these are generally well-tolerated
- Cost considerations exist, but cost-effectiveness analyses support HD vaccine use in this population 9
- Any influenza vaccine is vastly superior to no vaccine—if high-dose is unavailable, standard-dose vaccines remain highly valuable 10
Practical Algorithm
For patients ≥65 years presenting for influenza vaccination:
- First choice: High-dose Fluzone (or other high-dose/adjuvanted formulations)
- If high-dose unavailable: Standard-dose vaccine (including Mfluvisa/Flucelvax) is still strongly recommended
- Prioritize high-dose most strongly for:
- Adults ≥75 years
- Nursing home residents
- Those with cardiovascular disease or chronic conditions
- Frail elderly
The key message: High-dose Fluzone provides superior protection against influenza-related hospitalizations and complications in adults ≥65 years and should be the default choice when available 3, 4, 1, 2.